Thomvest-backed Structured Alpha, a fund managed by Thomvest, agreed to acquire the remaining shares of Liminal BioSciences, a development-stage biopharmaceutical company focused on discovering and developing novel and distinctive small molecule therapeutics. Financial terms were not disclosed. "After an extensive process led by a special committee comprised of disinterested and independent directors, we are pleased to have agreed terms on a transaction with SALP that has the full support of the Liminal BioSciences board. The transaction will deliver immediate value and liquidity to our minority shareholders at a substantial premium. Reaching this point is a testament to everything that the entire Liminal BioSciences team has accomplished. We look forward to partnering with SALP to continue to pursue our goal of developing and delivering cutting edge treatment to patients," Bruce Pritchard, Liminal BioSciences CEO.